Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Zhaoke Ophthalmology Ltd. has announced the completion of the Phase III clinical trial for TAB014, a promising treatment for wet age-related macular degeneration, with the last patient visit concluding on September 20, 2024. The trial, involving 488 patients across 57 centers, aims to compare the efficacy of TAB014 against the established Lucentis treatment. With wAMD being a major cause of vision loss and an expanding market for treatments in China, TAB014 positions itself as an innovative and cost-effective therapy, bolstered by a strategic agreement giving Zhaoke Guangzhou full control over the drug’s development and commercialization in China, Hong Kong, and Macau.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.
